Last checked at 30 Oct 2014 11:10
FOR IMMEDIATE RELEASE | 30 OCTOBER 2014 |
NOTIFICATION OF ODEY'S MAJOR INTEREST IN SHARES
Following the Recent Successful £3.4m Fund Raising
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that its long standing shareholder Odey Asset Management ("Odey") has increased its shareholding in ImmuPharma Ordinary Shares to 3,433,319 representing a 3.87% shareholding in the Company.
This follows last week's announcement from ImmuPharma that Odey with Aviva plc were lead investors in a £3.4 million fund raising to support the pivotal phase III progress of LupuzorTM, the Company's lead candidate for the treatment of lupus, a potentially life threatening auto-immune disease.
Commenting on this announcement, Richard Warr, Chairman said: "Odey has been a key investor in ImmuPharma since the Company's inception. We are therefore delighted to have received further support from this major shareholder for our plans to take LupuzorTM through its pivotal Phase III development."
For further information please see the Group's web site, www.immupharma.com, or contact:
ImmuPharma plc | + 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer | |
Dr Robert Zimmer, President and Chief Scientific Officer | |
Richard Warr, Chairman | |
Tracy Weimar, Vice President, Operations and Finance | |
Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 |
Panmure, Gordon & Co., NOMAD & Broker | +44 (0) 20 7886 2500 |
Hugh Morgan, Fred Walsh, Duncan Monteith |